AWT-020 by Anwita Biosciences for Sarcomas: Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AWT-020 overview

AWT-020 is under development for the treatment of NSCLC (non-small cell lung cancer), RCC (renal cell carcinoma), melanoma, colon carcinoma, breast cancer, urothelial carcinoma, sarcoma and hepatocellular carcinoma. It is a targeted fusion protein comprised of an anti-PD1 antibody linked to a potency optimized IL-2Na. It is being developed based on AccuKine and AccuBody platform and is administered through intravenous route.

Anwita Biosciences overview

Anwita Biosciences is an emerging biopharmaceutical company. The company is specialized in the discovery and development of optimized immuno-therapeutics, leveraging our core expertise in cancer immunotherapy, bioinformatics, and structure-based protein engineering. Anwita Biosciences is headquartered in San Carlos, California, the US.

For a complete picture of AWT-020’s drug-specific PTSR and LoA scores, buy the report here.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.